Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Arcutis Biotherapeutics (ARQT) Income from Continuing Operations (2020 - 2025)

Arcutis Biotherapeutics has reported Income from Continuing Operations over the past 6 years, most recently at 17366000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 17366000.0 for Q4 2025, up 260.98% from a year ago — trailing twelve months through Dec 2025 was 16170000.0 (up 88.45% YoY), and the annual figure for FY2025 was 16170000.0, up 88.45%.
  • Income from Continuing Operations for Q4 2025 was 17366000.0 at Arcutis Biotherapeutics, up from 7410000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for ARQT hit a ceiling of 17366000.0 in Q4 2025 and a floor of 107709000.0 in Q3 2022.
  • Median Income from Continuing Operations over the past 5 years was 48548500.0 (2023), compared with a mean of 46844300.0.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 109.27% in 2021 and later soared 260.98% in 2025.
  • Arcutis Biotherapeutics' Income from Continuing Operations stood at 71286000.0 in 2021, then fell by 1.03% to 72019000.0 in 2022, then grew by 7.98% to 66271000.0 in 2023, then skyrocketed by 83.72% to 10788000.0 in 2024, then soared by 260.98% to 17366000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 17366000.0 (Q4 2025), 7410000.0 (Q3 2025), and 15886000.0 (Q2 2025) per Business Quant data.